Paroxysmal Nocturnal Hemoglobinuria (PNH)
Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs
Clinical development of our investigational therapy, pegcetacoplan
Pegcetacoplan Bests Eculizumab for PNH Patients
Clinical Challenges: Paroxysmal Nocturnal Hemoglobinuria — Complement inhibitors a major advance but not a cure
Paroxysmal nocturnal haemoglobinuria (PNH): novel therapies for an ancient disease
In the UK, early work on paroxysmal nocturnal haemoglobinuria (PNH) was conducted by John Dacie who, at the Hammersmith Hospital, first hypothesised that the PNH abnormality might arise through a somatic mutation mutation:
Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria
Paroxysmal nocturnal hemoglobinuria Paroxysmal nocturnal hemoglobinuria: (pa
PNH - Traveling with a Rare Disease - Update from Josh
Traveling with a rare disease
Crovalimab
An experimental complement inhibitor C5 monoclonal antibody monoclonal antibody: A type of protein called an antibody that is engineered to look for a speci
